Meeting Coverage:

Aspen Retinal Detachment Society

ARDS: 2019

Anti-VEGF Treatment for Diabetic Retinopathy: Consequences of Inadvertent Treatment Interruptions

Show Description +

Mark W. Johnson, MD, sits down with Timothy G. Murray, MD, MBA, to review his talk on the differences between panretinal photocoagulation and anti-VEGF therapy in patients with diabetic retinopathy. Dr. Johnson contrasts differences between the two therapies as long-term treatment options, and discusses data from a pair of studies that examined the visual outcomes of patients with diabetic eye disease who were lost to follow-up for extended periods.

Posted: 3/05/2019

Up Next

New Therapies in Wet AMD

Peter K. Kaiser, MD, Timothy G. Murray, MD, MBA


ILM Peeling in Macular Hole Surgery: When and How

David HW Steel, MBBS, FRCOphth, Timothy G. Murray, MD, MBA

Endophthalmitis: Clinical Cases and Management Strategies

Harry W. Flynn Jr, MD, Timothy G. Murray, MD, MBA

Anti-VEGF Treatment for Diabetic Retinopathy: Consequences of Inadvertent Treatment Interruptions

Mark W. Johnson, MD, sits down with Timothy G. Murray, MD, MBA, to review his talk on the differences between panretinal photocoagulation and anti-VEGF therapy in patients with diabetic retinopathy. Dr. Johnson contrasts differences between the two therapies as long-term treatment options, and discusses data from a pair of studies that examined the visual outcomes of patients with diabetic eye disease who were lost to follow-up for extended periods.

Posted: 3/05/2019


Please log in to leave a comment.

More From ARDS: 2019 Coverage